• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Jain Rita

    6/18/25 4:00:57 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jain Rita

    (Last) (First) (Middle)
    C/O AVALO THERAPEUTICS, INC.
    1500 LIBERTY RIDGE DRIVE, SUITE 321

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/17/2025
    3. Issuer Name and Ticker or Trading Symbol
    Avalo Therapeutics, Inc. [ AVTX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Donald R. Reynolds, by Power of Attorney 06/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTX

    DatePrice TargetRatingAnalyst
    6/2/2025$15.00Buy
    H.C. Wainwright
    3/25/2025$36.00Buy
    Stifel
    3/25/2025$23.00Buy
    Jefferies
    2/28/2025$48.00Overweight
    Piper Sandler
    2/21/2025$18.00Outperform
    Wedbush
    12/19/2024$40.00Buy
    BTIG Research
    10/24/2024Neutral
    H.C. Wainwright
    4/16/2024$35.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Avalo Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $15.00

      6/2/25 8:50:04 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Avalo Therapeutics with a new price target

      Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Avalo Therapeutics with a new price target

      Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    SEC Filings

    See more
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      6/20/25 7:08:35 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      6/18/25 7:01:16 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      6/17/25 4:01:23 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Truex Samantha

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      6/18/25 4:44:17 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chan Mitchell

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      6/18/25 4:39:54 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Goldman Jonathan

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      6/18/25 4:35:44 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

      WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

      6/18/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics to Participate in Upcoming Investor Conferences

      WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: "Dermatology: AA, HS, PSO"June 25, 2025, at 10am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available f

      5/27/25 10:05:34 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

      Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025. "We have made considerable progress in our Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with site activations, screenings

      5/12/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care